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Abstract
Background: Synucleinopathies of the aging population are an heterogeneous group of neurological disorders that
includes Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) and are characterized by the progressive
accumulation of α-synuclein in neuronal and glial cells. Toll-like receptor 2 (TLR2), a pattern recognition immune
receptor, has been implicated in the pathogenesis of synucleinopathies because TLR2 is elevated in the brains of
patients with PD and TLR2 is a mediator of the neurotoxic and pro-inflammatory effects of extracellular α-synuclein
aggregates. Therefore, blocking TLR2 might alleviate α-synuclein pathological and functional effects. For this purpose,
herein, we targeted TLR2 using a functional inhibitory antibody (anti-TLR2).
Methods: Two different human α-synuclein overexpressing transgenic mice were used in this study. α-synuclein low
expresser mouse (α-syn-tg, under the PDGFβ promoter, D line) was stereotaxically injected with TLR2 overexpressing
lentivirus to demonstrate that increment of TLR2 expression triggers neurotoxicity and neuroinflammation. α-synuclein
high expresser mouse (α-Syn-tg; under mThy1 promoter, Line 61) was administrated with anti-TLR2 to examine that
functional inhibition of TLR2 ameliorates neuropathology and behavioral defect in the synucleinopathy animal model.
In vitro α-synuclein transmission live cell monitoring system was used to evaluate the role of TLR2 in α-synuclein
cell-to-cell transmission.
Results: We demonstrated that administration of anti-TLR2 alleviated α-synuclein accumulation in neuronal and
astroglial cells, neuroinflammation, neurodegeneration, and behavioral deficits in an α-synuclein tg mouse model
of PD/DLB. Moreover, in vitro studies with neuronal and astroglial cells showed that the neuroprotective effects
of anti-TLR2 antibody were mediated by blocking the neuron-to-neuron and neuron-to-astrocyte α-synuclein
transmission which otherwise promotes NFκB dependent pro-inflammatory responses.
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Conclusion: This study proposes TLR2 immunotherapy as a novel therapeutic strategy for synucleinopathies of
the aging population.
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Background
Following Alzheimer’s Disease (AD), synucleinopathies
such as Parkinson’s disease (PD) and dementia with Lewy
bodies (DLB) are the second most common group of neu-
rodegenerative disorders of the aging population [1]. Over-
all, they represent heterogeneous group of neurological
conditions, characterized by progressive accumulation of
α-synuclein in neuronal and glial cells, selective neuronal
degeneration, and neuroinflammatory responses [1–4].
The mechanisms through which the various species of
α-synuclein aggregates lead to selective neurodegeneration
and neuroinflammation is not completely understood
[5, 6]. However, previous studies suggest that α-synuclein
oligomers might trigger synaptic dysfunction by interfering
with endo-lysosomal transport, mitochondrial function,
and calcium dysregulation [5]. Moreover, transmission
of α-synuclein aggregates from neuron-to-neuron and
neuron-to-glia has been suggested as the underlying
mechanism of the neurodegeneration and neuroinflam-
mation in synucleinopathy [1].
We have previously shown that the oligomeric forms of
extracellular α-synuclein interact with Toll-like receptor 2
(TLR2) on the surface of neurons and glial cells [7, 8].
While engagement of neuronal TLR2 by extracellular
α-synuclein resulted in neurodegeneration by inhibition
of autophagy via AKT/mTOR signaling [8], extracellular
α-synuclein activated microglia through TLR2 signaling
via NFκB and p38 MAPK, thereby resulted in neuro-
inflammatory responses with TNFα and IL-6 productions
[7]. In addition, recent studies suggested that other recep-
tors such as lymphocyte-activation gene 3 (LAG3) might
mediate the pathological effects of α-synuclein transmis-
sion [9].
TLR2 belongs to a family of pattern recognition receptor
which modulate responses to exogenous pathogens as well
as endogenous misfolded proteins released following dam-
age and cellular stress [10]. In the central nervous system,
TLR2 is expressed in glial cells and neuronal populations,
and recent studies have shown that the levels of TLR2 are
elevated in neurodegenerative disorders such as AD and PD
[11–14]. Single nucleotide polymorphism in the TLR2 gene
has also been associated with PD [15]. Moreover, we have
recently shown that inhibition of TLR2 by gene deletion
or siRNA-mediated knock down rescues the pathology as-
sociated with α-synuclein accumulation in cellular models
and transgenic mice [8]. Therefore, TLR2 and downstream
signaling have been suggested a new therapeutic target for
synucleinopathy [7, 8, 16].
In addition to approaches modulating TLR2 activity by
genetic manipulations such as siRNA, more recent stud-
ies have also proposed the use of small organic mole-
cules that antagonize TLR2 signaling [17]. While these
approaches have some advantages, the main drawback is
the low CNS penetration ration and the non-selectivity
of small molecules. As an alternative, recent studies have
suggested that the immunotherapy blocking α-synuclein
[18] and modulating the immune responses might hold
some value [19]. For example, neutralizing TLR2 with a
monoclonal antibody has been recently shown to ameli-
orate the pathology in a murine model of AD [14].
We have previously shown that α-synuclein oligomers
propagate from neuron to glial cells engaging the TLR2
and promoting inflammation which reduced in the TLR2
knockout background [8], however it is unclear if immuno-
therapy with TLR2 antibodies might rescue the complex
pathology in models of synucleinopathy. In this context,
the main objective of this study was to evaluate the thera-
peutical effects of targeting TLR2 with a functional inhibi-
tory antibody (anti-TLR2) and to better understand the
mechanisms action of the immunotherapy by investigating
the role of TLR2 dependent pro-inflammatory signaling of
extracellular α-synuclein via NFκB. We show that the ad-
ministration of anti-TLR2 was able to decrease the accu-
mulation of neuronal and astroglial α-synuclein, resulting
in reduced neuroinflammation, neurodegeneration, and
behavioral deficits in an α-synuclein transgenic mouse
model of PD/DLB. Moreover, the anti-TLR2 blocked
the neuron-to-neuron and neuron-to-astrocyte α-synuclein
transmission and reduced the NFκB dependent pro-
inflammatory responses in cell based model. Therefore,
TLR2 might be a viable target and TLR2 immunother-
apy is a novel therapeutic strategy for synucleinopathies
of the aging population.
Methods
Antibodies and chemicals
Pam3CSK4 was purchased from InvivoGen (San Diego,
CA). The following antibodies were used for western
blot analysis, immunostaining analysis, and animal model
injection: α-synuclein (Syn-1; BD Bioscience, San Diego,
CA), α-synuclein (Syn211), β-actin (Sigma-Aldrich), NeuN,
GFAP (GA5), Tyrosine Hydroxylase (Millipore, County
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Cork, Ireland), Iba1 (Wako, Richmond, VA), TLR2, IL-6,
phosphor-NFκB (Abcam, Cambridge, MA), TLR2 (clone
T2.5), IgG (eBioscience, San Diego, CA), Active-caspase
3 (R&D systems, Minneapolis, MN), Venus-GFP, and
phosphor-p38 MAPK (Cell signaling, Danvers, MA).
Human specimens, neuropathological evaluation and
criteria for diagnosis
Human specimens (8 non-demented controls and 8
PD/DLB cases) were obtained from Alzheimer Disease
Research Center/University of California, San Diego.
The diagnosis of PD/DLB was based on the initial clinical
presentation with dementia followed by parkinsonism and
the presence of α-synuclein and ubiquitin positive Lewy
bodies in cortical and subcortical regions [20].
Delivery of lentiviral vectors into mice brain
To determine the role of TLR2 in α-synuclein pathology,
we delivered either LV-control or LV-TLR2 into non-tg
and α-syn-tg mice expressing human wild-type α-synuclein
under the PDGF-β promoter (D line) [21]. Two microliters
of either LV-control or LV-TLR2 (2.2 × 107 infection units)
was bilaterally stereotaxically injected into the hippocampus
(anterior-posterior [AP], − 2.0 mm; medial-lateral [ML],
1.5 mm; and dorsal-ventral [DV], − 1.3 mm). After 5 weeks
post injection, mice brains were processed for immunohis-
tochemistry and biochemical analysis. The right hemi-
brains were post-fixed in phosphate-buffered 4% PFA at
4 °C for neuropathological analysis, while the left hemi-
brains were snap-frozen and stored at − 70 °C for biochem-
ical analysis. All procedures for animal use were approved
by the institutional Animal Care and Use Committee at
University of California, San Diego under protocol S02221.
Synucleinopathy mouse model and anti-TLR2 treatment
Transgenic mice overexpressing wild-type human α-
synuclein under the mThy1 promotor (α-Syn-tg, Line
61) were used for TLR2 passive immunization analysis
since mice develop α-synuclein accumulation in cortical/
subcortical regions, neuroinflammation, neurodegener-
ation, and behavioral deficits [22–24]. Nine-month old
mice were injected intraperitoneally (IP) with either
control IgG or T2.5 antibodies (5 mg/kg) once a week
for 4 weeks. At the end of the study, mice were tested
for behavioral defect. Upon termination, the right
hemi-brains were post-fixed for neuropathological ana-
lysis and the left hemi-brains were stored at − 70 °C for
biochemical analysis. All procedures for animal use
were approved by the institutional Animal Care and




The procedures for immunohistochemical, immunofluor-
escence, double-immunolabeling, and neuropathological
analysis have been described elsewhere [25]. Briefly,
blind-coded sagittal brain sections were incubated with
primary antibodies at 4 °C for overnight. To detect protease
K (PK) resistant α-synuclein aggregates, sections were
pre-treated with PK (10 μg/ml) for 8 min as previously de-
scribed [26]. The next day, sections were incubated with ei-
ther biotinylated-, FITC-conjugated, Texas-red-conjugated
secondary antibodies or detected with avidin D-HRP (ABC
elite, Vector Laboratories, Burlingame, CA) and with
Tyramide Signal Amplification Direct system (PerkinElmer,
Waltham, MA), respectively. Sections were imaged by
Olympus BX41 microscope. All immunoreactivity levels
were determined by optical density analysis using Image
Quant 1.43 program (NIH). The cell numbers of GFAP,
Iba-1, and NeuN-positive cells were determined per field
(230 μm × 184 μm) for each animal based on cell body
recognition using Image Quant 1.43 program (NIH).
Preparation of tissue extract and western blot analysis
The procedures for tissue extraction preparation and
western blot analysis have been described elsewhere [8].
Briefly, whole brain homogenates were prepared in the
1% triton-containing lysis buffer, then sonicated. The
proteins were separated by electrophoresis and transferred
to PVDF membranes using semi-dry Trans-Blot Turbo
Transfer System (Bio-Rad, Hercules, CA). Membranes
were blocked with Odyssey blocking buffer (LI-COR
Biosciences, Lincoln, NE) and probed with primary and
followed by fluorescence-tagged secondary antibody. The
fluorescent signal detection and densitometric analysis were
performed using ODYSSEY CLx (LI-COR Biosciences) and
Image Studio (LI-COR Biosciences).
Behavioral analysis
The evaluation of behavioral defects of synucleinopathy
mouse model has been previously described elsewhere
[8, 27]. Briefly, to evaluate hyperactivity and anxiety-like
behavior of synucleinopathy mouse model, animals were
tested in the open field apparatus. Data was collected
using a Kinder Smart Frame Cage Rack Station activity
monitor system (Kinder Scientific, Poway, CA). Data col-
lection began when an animal was placed in the test
chamber. Animals were evaluated for 10 min to deter-
mine total activity, latency, and percentage of the time
in the periphery vs the center of the box (Thigmotaxis).
Cell cultures and lentiviral vector infections
The maintenance and differentiation of human SH-SY5Y
neuroblastoma, human primary astrocytes, and mouse pri-
mary cortical neurons were previously described [7, 8, 28].
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Construction and maintenance of V1S and SV2 cells
have been described elsewhere [29]. Construction and
preparation of lentiviral vectors (LV-control, LV-sh.control,
LV-α-Syn, LV-sh.TLR2, and LV-TLR2) have been previously
described [8, 30]. To deliver lentiviral vectors, cells
were infected with viral vectors at multiplicity of infection
of 100 (LV-control and LV-α-Syn) and 50 (LV-sh.control,
LV-sh.TLR2, and LV-TLR2).
In vitro live α-synuclein cell-to-cell transmission
monitoring assay
V1S (1.25 × 105) cells were seeded onto trans-well inserts
(Corning, Corning, NY) and either SV2 (1.25 × 105) or
human primary astrocytes (2.3 × 104) cells were placed
in lower compartments on poly-L-lysine-coated glass cov-
erslips. The next day, the trans-well inserts were moved
onto the lower compartment to start the co-culture. The
lower compartments were harvested at the indicated time
point. After incubation, coverslips were fixed with parafor-
maldehyde (4%) for 30 min in the dark. Fixed SV2 cells
were also single immunolabelled against active caspase-3.
Fixed human astrocytes were double-immunostained with
anti-N-term-venus and anti-IL-6. Coverslips were imaged
with a laser scanning confocal microscope Zeiss 800 (Carl
Zeiss, Oberkochen, Germany) at 900× magnification. An
average 10 fields were analyzed per condition and Image J
program was used to determine the pixel intensity. At first
images were converted to gray scale then inverted and a
mask generated to segment the two cellular compart-
ments. Then the region of interest in the cellular compart-
ment was traced semi-automatically and a threshold was
applied followed by estimation of pixel intensity. The di-
ameters of venus punctum were analyzed using Zen pro-
gram (Carl Zeiss). At least 300 puncta (100 puncta per set,
total 3 sets per condition) were analyzed.
α-Synuclein internalization analysis
dSY5Y neuronal cell, human primary astrocyte, or mouse
primary neuron was treated with either LZCM or αSCM
(α-synuclein concentration: approximate 1 μg/ml) [7] for
indicated hours in the presence of either IgG (5 μg/ml) or
T2.5 (5 μg/ml). After an incubation, cells were washed
with PBS for 3 times and fixed with 4% PFA. The fixed
cells were immunolabelled with antibodies against human
α-synuclein, active caspase-3, and/or N-terminus of venus.
Coverslips were analyzed with microscope Zeiss 800 (Carl
Zeiss) at 900× magnification.
Quantitative polymerase chain reaction
Extraction of total RNAs and preparation of cDNA
from mice brains and cultured cells have been de-
scribed previously [8, 25]. Quantitative real-time PCR was
performed using TaqMan® Fast Advanced Master Mix (Life
Technologies) according to manufacturer’s instruction with
gene specific primers obtained from Life Technologies,
such as TNFα (Mm00443258_m1), IL-1β (Mm00434228_m1
and Hs01555410_m1), IL-6 (Mm00446190_m1 and
Hs00174131_m1), CX3CL1 (Hs00171086_m1), CCL5
(Hs00982282_m1) and β-actin (Mm00607939_s1 and
Hs03023880_g1). Amplification of DNA products was
measured by the StepOnePlus real-time PCR system
(Applied Biosystems, Carlsbad, CA). Relative mRNA
levels were calculated according to the 2-exp (ΔΔCt)
method. All ΔCT values were normalized to β-actin.
Statistical analysis
InStat (GraphPad Software, San Diego, CA) was used for
all statistical analysis. All data were analyzed for statistical
significance by using either unpaired t test or one-way
ANOVA. All data are presented as means ± SEM.
Results
TLR2 expression is similarly increased in neuronal and glial
cells in α-synuclein transgenic models as is in the brains of
patients with PD/DLB
We have previously shown that TLR2 might mediate the
neurotoxic and pro-inflammatory effects of α-synuclein
oligomers [8] and it has been recently reported that
levels of TLR2 expression are increased in the brains of
patients with synucleinopathy [11–13]. Therefore, antag-
onizing TLR2 might be able to reverse or prevent the
pathological cascades triggered by α-synuclein oligomers.
To further validate this possibility, we analyzed the levels
of TLR2 in the brains of PD/DLB patients (Fig. 1a-c)
and in a transgenic mouse model expressing high levels
(3–4 fold) of human α-synuclein under the mThy1 pro-
moter (α-Syn-tg; Line 61) using immunolabeling analysis
(Fig. 1d-f) [23]. This α-Syn-tg model (high expresser of
α-synuclein) was selected because the mice develop
neurodegenerative, neuro-inflammatory, and behavioral
deficits similar to patients with PD/DLB [31]. The neo-
cortex of PD/DLB patients and α-Syn tg mice were
double-immunolabelled against TLR2 and various cel-
lular markers, such as NeuN (neuron, Fig. 1a and d),
GFAP (astrocyte, Fig. 1b and e), and Iba-1 (microglia,
Fig. 1c and f). We found that TLR2 expression was in-
creased in pyramidal neurons in the neocortex of patients
with PD/DLB and in the α-Syn-tg mice (Fig. 1a and d).
Moreover, we found that expression of TLR2 was in-
creased in astrocytes (Fig. 1b and e) and in microglia
(Fig. 1c and f ) of disease-affected human and mouse
brains. Together, these results show comparable increases
of TLR2 expression in neurons and glial cells in PD/DLB
patients and in the high expresser α-Syn-tg mice and
provides rationale to the notion that blocking TLR2 with
neutralizing antibodies might be of therapeutic value.
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Overexpression of TLR2 aggravates α-synuclein and
related neuropathology in wild-type mice and α-synuclein
low expresser transgenic mice
To further demonstrate that increasing TLR2 expression
triggers neurotoxic and neuro-inflammatory cascades
similar to those observed in patients with PD/DLB and
in high expresser α-synuclein mouse model line (Fig. 1),
we next delivered a TLR2-overexpressing lentiviral vector
(LV-TLR2) into the brains of non-tg and an α-synuclein
low expresser (1–1.5 fold) transgenic mouse (α-syn-tg,
under the PDGFβ promoter, D line) (Fig. 2; Additional file 1:
Figure S1) [23]. This α-syn-tg was selected because the
lower levels of α-synuclein expression allowing to analyze
combinatorial effects with viral vector mediated TLR2
overexpression, moreover we have previously shown that
this model mimics aspects of DLB neuropathology and
that knocking down TLR2 with shRNA is protective [8].
Either control virus (LV-control) or LV-TLR2 was stereo-
taxically injected into non-tg and α-syn-tg mice, and then
neuropathology was analyzed after a 5-week post injection
(Additional file 1: Figure S1a). Delivery of LV-TLR2 in-
creased expression of TLR2 in both α-synuclein-expressing
neurons and neighboring glial cells (Additional file 1:
Figure S1b and c). Compared to α-syn-tg mice injected
with LV-control, the tg mice injected with the LV-TLR2
displayed a dramatic increase in the accumulation of
α-synuclein in the neocortex and hippocampus (Fig. 2a).
These α-syn-tg mice also display mild neurodegeneration
and glial cell activation [32]. Consistent with these find-
ings, compared to the non-tg injected with LV-control,
the present study reports mild astrogliosis and microglio-
sis in the neocortex and hippocampus of the LV-control
injected α-syn-tg mouse brains with overexpression of
TLR2 considerably increasing neuro-inflammation both in
the α-syn-tg mice, but also in non-tg mice (Fig. 2b and c).
Interestingly, compared to the non-tg injected with
LV-control, the non-tg mice injected with the LV-
TLR2 displayed loss of NeuN positive neurons in the
Fig. 1 Expression of TLR2 in the neocortex of synucleinopathy patients and an animal model. a–c Representative images from double-immunolabeling
for TLR2 with cellular markers in the neocortex of normal and PD/DLB patients. The percentages of TLR2-positive neurons (NeuN) (a), astrocytes (GFAP)
(b), and microglia (Iba1) (c) in the neocortex (n= 8 per group). d–f Representative images from double-immunolabeling for TLR2 with cellular markers in
the neocortex of non-tg and α-Syn-tg (Line 61) mice (9–10 month olds). The percentages of TLR2-positive neuron (NeuN) (d), astrocyte (GFAP) (e), and
microglia (Iba1) (f) in the neocortex (n= 6 per group). Data are mean ± SEM. *p < 0.05, **p< 0.01, and ***p< 0.001; unpaired t test. Scale bar, 20 μm
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hippocampus and neocortex (Fig. 2). As to the
LV-control injected α-syn-tg mice, we found loss of
neurons in the hippocampus and neocortex when
compared to the LV-control injected non-tg mice,
however no greater loss of NeuN was observed in the
LV-TLR2 injected α-syn-tg mice. (Fig. 2d). We have
previously shown [33] that neuron-inflammation and
neurodegeneration of this α-syn-tg mice were associated
with α-synuclein transfer to astroglial cells, in this context
we next investigated if the LV-TLR2 injection will enhance
this effect. As expected, no accumulation of α-synuclein
was observed in the brain of the lentiviral vector-injected
non-tg mice, in contrast LV-control injected α-syn-tg mice
displayed discrete accumulation of α-synuclein in glial-like
cells and LV-TLR2 injection resulted in a 2.5 fold increase
in the brain of α-syn-tg (Additional file 1: Figure S2a). To
confirm the identity of these cells, double labeling with
anti-GFAP and confocal microscopy was performed. This
study confirmed that in the LV-control injected α-syn-tg
mice, the α-synuclein in the glial-like cells co-localizes
with GFAP and that in tg mice injected with LV-TLR2
there is a considerable increase in α-synuclein/GFAP
co-localization (Additional file 1: Figure S2b). Collectively,
these results support the concept that increase TLR2 ex-
pression might play a role in mediating the neurotoxic
and pro-inflammatory effects of α-synuclein. Therefore, it
is possible that blocking TLR2 might be of value at ameli-
orating the pathology associated with α-synuclein accu-
mulation in neurons and glial cells.
TLR2 passive immunization ameliorates neuropathology
and behavioral defect in synucleinopathy mouse model
Together with previous studies [8, 34], our current find-
ings support the idea that levels of TLR2 play an import-
ant role in promoting the neurodegenerative pathology
and deficits in models of synucleinopathy, therefore, we
hypothesized that if functional inhibition of TLR2 would
reduce overall burden of those pathologies in the model
Fig. 2 Neuropathology analysis of LV-TLR2-delivered non-tg and α-syn-tg mice. Either LV-control or LV-TLR2 was injected into the hippocampus
of non-tg or α-syn-tg mice (D line). a–d Representative images from immunohistochemical staining of α-synuclein (a), Iba-1 (b), GFAP (c), and
NeuN (d) in the neocortex and hippocampus of lentiviral vector-delivered mice. The level of α-synuclein (a) or GFAP (c) was analyzed in the
neocortex and hippocampus of the mice by optical density quantification. The number of Iba-1 (b) or NeuN (d) positive cell was counted in
neocortex and hippocampus of the mice. Data are mean ± SEM (n = 6 per group). *p < 0.05, **p < 0.01, and ***p < 0.001; one way ANOVA. Scale
bars, 250 μm (low magnification) and 25 μm (high magnification)
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of synucleinopathy. To test this hypothesis, we adminis-
trated anti-TLR2 antibody (T2.5, a TLR2 functional
blocking antibody) to high expresser α-Syn-tg (Line 61),
which mimics neuropathological and functional aspects
of PD/DLB including neuroinflammation and increased
TLR2 expression (Fig. 1d-f ). For this purpose, non-tg or
α-Syn tg mice were injected intraperitoneally with either
control IgG or T2.5 antibodies (5 mg/kg) weekly for 4
times (Fig. 3a). Approximate 1% of injected antibody
may reach the brain according to previous antibody ther-
apy studies [22, 30, 32, 35]. At the end of the study, mice
were tested for behavioral effects. Upon termination, the
brains were analyzed for biochemical and neuropatho-
logical analysis (Fig. 3a).
Compared to IgG treated α-Syn-tg mice, injection of
anti-TLR2 significantly reduced the neuronal accumula-
tion of α-synuclein in the neocortex and hippocampus
of the α-Syn-tg mice (Fig. 3b). Furthermore, the levels of
accumulation of PK-resistant α-synuclein were reduced
by anti-TLR2 administration in the neocortex and
hippocampus of α-Syn-tg mice, while it was not detected
in antibody administrated non-tg mice (Fig. 3c). Likewise,
immunoblotting analysis demonstrated that the levels of
triton-insoluble high molecular weight α-synuclein oligo-
mers were significantly reduced in the neocortex of α-Syn-tg
mouse model after anti-TLR2 administration (Fig. 3d), while
triton-soluble and -insoluble α-synuclein monomer was not
affected by anti-TLR2 treatment (Fig. 3d).
In addition to the neuronal α-synuclein accumulation
in cortical and subcortical brain regions, the higher ex-
presser α-Syn-tg mouse model also displays neuroinflam-
matory pathology and α-synuclein accumulation in glial
cells [25] similar to that of patients with PD/DLB [36].
Compared to non-tg mice, the IgG treated α-Syn-tg mice
displayed extensive astrogliosis and microgliosis (Fig. 4a)
which was reduced by administration of anti-TLR2
(Fig. 4a). Although microglia, a brain resident immune
cell, has been regarded as a major source of cytokine
expression, recent studies have shown that astrocyte
also could produce inflammatory cytokines and chemo-
kines in response to stimulus [33]. Double immunolabeling
analysis against astrocyte marker (GFAP) and IL-6 demon-
strated that compared to non-tg mice in the IgG treated
α-Syn-tg animals there was an elevation of astroglial
IL-6 which was reduced in mice treated with anti-TLR2
(Fig. 4b).
In PD/DLB [36] and tg models [33], previous studies
have shown that α-synuclein accumulates not only in
neurons but also in glial cells Moreover, we have shown
α-synuclein transmits from neuron to glial cells [37], that
this is enhanced by TLR2 overexpression (Additional file 1:
Figure S2) and that this might result in neuro-
inflammation in models of synucleinopathy [33]. Consist-
ent with this possibility, double labeling studies showed
that compared to non-tg controls, in IgG treated
α-Syn-tg there was considerable co-localization of
human-α-synuclein in GFAP-positive astrocytes, in
contrast treatment with T2.5 significantly reduced the
astroglial accumulation of α-synuclein in the α-Syn-tg
(Fig. 4c).
Next, we investigated levels of pro-inflammatory cyto-
kines expression, such as IL-1β, TNFα, and IL-6. We
found that compared to non-tg mice, in the IgG treated
α-Syn-tg mice there was an increase in the levels of
IL-1β, TNFα, and IL-6 expression, however, treatment
with the anti-TLR2 antibody normalized levels in the
α-Syn-tg compared to non-tg mice (Fig. 4d-f ). Consist-
ent with the gene expression findings, immunoblotting
analysis demonstrated activation of NFκB and increased
IL-6 levels in IgG treated α-Syn-tg mice compared to
non-tg controls, while anti-TLR2 administration in the
α-Syn-tg showed a reduction in NFκB activation and
production of IL-6 comparable to non-tg mice (Fig. 4g).
Following this step, we analyzed if anti-TLR2 adminis-
tration had effects on the neurodegenerative pathology
in the α-Syn-tg mice (Fig. 5). We have previously shown
that these mice develop loss of neurons in the deeper
layers of the neocortex and CA3 of the hippocampus
[38] and loss of Tyrosine hydroxylase (TH)-fibers in the
striatum [24]. Compared to non-tg mice, IgG treated
α-Syn-tg mice displayed loss of neurons in the neocortex
and hippocampus that was prevented by the treatment
with anti-TLR2 (Fig. 5a). Likewise, compared to non-tg
mice, IgG treated α-Syn-tg mice displayed loss of TH-
positive fibers in the striatum and anti-TLR2 adminis-
tration significantly ameliorated the loss of TH-positive
fibers in the α-Syn-tg (Fig. 5b). Consistent with previous
studies, no difference was observed in the numbers of TH
positive neurons in the substantia nigra of antibody-
administrated non-tg and α-Syn-tg mice (Fig. 5b). In
agreement with the immunocytochemical evaluation of
neurodegeneration, immunoblotting analysis of brain ho-
mogenates also demonstrated that compared to non-tg
mice, the active form of caspase-3 was increased in the
IgG treated α-Syn-tg, however anti-TLR2 administration
normalized levels in the α-Syn-tg to those observed in
non-tg mice (Fig. 5c).
To determine if the reduction of neuropathology had
functional consequences, we performed open filed test
to evaluated the total activity and anxiety-like behavior
of α-Syn-tg mouse model (Fig. 5d-f ). We have previously
shown that neurodegeneration and neuro-inflammation
in these mice is associated with hyper-activity [24]. Com-
pared to non-tg mice the IgG treated α-Syn-tg showed a
significant increment of the total activity (Fig. 5d). Treat-
ment of α-Syn-tg with anti-TLR2 clearly normalized the
total activity to levels comparable to the non-tg mice
(Fig. 5d). Similarly, compared to non-tg mice, the latency
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Fig. 3 Administration of anti-TLR2 (T2.5) decreases α-synuclein pathology in a synucleinopathy mouse model. a Experimental scheme. Non-tg and
α-Syn-tg (Line 61) mice were administrated with either IgG (5 mg/kg) or T2.5 (5 mg/kg) weekly for 4 weeks. The levels of α-synuclein pathology, glial
cell reactivity, neurodegeneration, and behavioral deficits were analyzed after a 5-weeks post injection. b Representative images from
immunohistochemical staining of α-synuclein in the neocortex and hippocampus of mice. The level of α-synuclein was analyzed by optical
density quantification (n = 6 per group). c Representative images from immunohistochemical staining of PK-resistant α-synuclein in the
neocortex and hippocampus of mice. The levels of PK-resistant α-synuclein were analyzed by optical density quantification (n = 6 per
group). d Immunoblot analysis of mice brain lysates. Triton-soluble and -insoluble brain lysates were probed for α-synuclein and β-actin.
The levels of triton-insoluble α-synuclein monomer and high molecular weight oligomers were determined by densitometric quantification (n = 4 per
group). Data are mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001, n.d. not detected; one way ANOVA for (b, d) and unpaired t test for (c). Scale bars,
250 μm (low magnification) and 25 μm (high magnification)
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level was increased in IgG treated α-Syn-tg, while anti-
TLR2 administration significantly normalized this behav-
ior (Fig. 5e). Finally, the levels of thigmotaxis (a marker of
anxiety) were not altered by α-synuclein overexpression as
well as antibody administration in the mice (Fig. 5f).
Collectively, these results suggest that targeting TLR2
by immunotherapeutic approach decreased accumulation
of neurotoxic α-synuclein aggregates and neuroinflamma-
tion, thereby ameliorating neurodegeneration and behav-
ioral defects in an animal model of synucleinopathy.
Neutralizing TLR2 inhibits abnormal accumulation of
neurotoxic α-synuclein in neuron
In this study, we showed that α-synuclein neuropathol-
ogy was modulated by TLR2 in the α-Syn-tg model and
the alterations rescued by an anti-TLR2 antibody. The
α-synuclein pathology was significantly increased by TLR2
overexpression, however, decreased by its functional inhib-
ition. Therefore, we proposed two potential mechanisms as
to how TLR2 modulate α-synuclein pathology. First,
neuronal TLR2 might modulates pathological α-synuclein
Fig. 4 Administration of anti-TLR2 (T2.5) decreases neuroinflammation in synucleinopathy mouse model. Non-tg or α-Syn-tg (Line 61) mice were
administrated with either IgG (5 mg/kg) or T2.5 (5 mg/kg) weekly for 4 weeks. a Representative images from immunohistochemical staining of
GFAP and Iba-1 in the hippocampus of mice. The level of GFAP was analyzed by optical density quantification and the number of Iba-1 positive
cell was counted in the hippocampus of mice (n = 6 per group). b Representative images from co-localization of GFAP (green) and IL-6 (red) in
the antibody-administrated mice. The percentages of GFAP/IL-6 double positive cells were analyzed in the hippocampus of mice. (n = 6 per
group). c Double immunolabeling analysis for human α-synuclein (green) and GFAP (red) in tg mice. The percentages of α-synuclein and GFAP
positive cells were analyzed in the hippocampus of tg mice (n = 6 per group). d–f Quantitative analysis of the cytokine gene expressions in the
cortex of mice. The expressions of IL-1β (d), TNFα (e), and IL-6 (f) were normalized to the levels of β-actin (n = 4 per group). g Immunoblot analysis of
the whole brain lysates probed for NFκB, IL-6, and β-actin. The levels of NFκB and IL-6 were determined by densitometric quantification (n = 3 per
group). Data are mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001; one way ANOVA for (a, d–g) and unpaired t test for (b and c). Scale bars, 250 μm
(low magnification) and 25 μm (high magnification)
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accumulation through intra-neuronal signaling. Second,
TLR2 may mediate neuron-to-neuron and neuron-to-glial
α-synuclein propagation. We previously demonstrated
that neuronal TLR2 modulated α-synuclein through au-
tophagy inhibition [8]. Therefore, herein, we examined the
roles of neuronal TLR2 in the pathological neuron-to-
neuron α-synuclein propagation (Fig. 6). To verify our hy-
pothesis, we first modulated the activity and expression of
TLR2 in in vitro α-synuclein transmission live cell monitor-
ing system that we developed and refer to as the dual-cell
bimolecular fluorescence complementation (BiFC) system
(Fig. 6a; Additional file 1: Figure S3a) [29, 39]. The system
consists of neuronal donor cells (V1S) and neuronal recipi-
ent cells (SV2). V1S cells are expressing α-synuclein conju-
gated with amino-terminal fragment of venus (VN-α-syn)
and SV2 cells are expressing α-synuclein conjugated with
carboxy-terminal fragment of venus conjugated α-synuclein
(α-syn-VC). Upon combining, the two proteins form the
complete Venus fluorescence molecule (Additional file 1:
Figure S3a). We previously have shown that this venus
puncta is also human α-synuclein, phosphor-α-synuclein,
and ubiquitin positive [29]. In addition, venus complemen-
tation did not observed when the V1S and SV2 cells were
co-cultured with N-terminal (V1) or C-terminal venus only
expressing (V2) cells [29]. Cell-to-cell transmission and the
resulting co-aggregation between the transferred and
endogenous α-synuclein proteins can be visualized and
quantitatively analyzed by monitoring the Venus fluores-
cence (Additional file 1: Figure S3a). To avoid physical
contacts between donor and recipient cells, the V1S and
the SV2 cells were incubated in trans-well inserts and in
lower compartments, respectively separated by a 0.4 μm
pore membrane (Additional file 1: Figure S3b). In support
of the validity of this system, the levels of Venus fluores-
cence in the recipient cells increased in proportion to the
duration of co-culture, while fluorescence was not de-
tected in single cell cultures (Additional file 1: Figure S3c).
To examine the role of TLR2 in neuron-to-neuron
α-synuclein transmission, we activated TLR2 using a
conventional agonist, pam3CSK4 (Fig. 6b). Treatment
Fig. 5 Neuroprotective effect of anti-TLR2 (T2.5) treatment in synucleinopathy mouse model. Non-tg or α-Syn-tg (Line 61) mice were administrated
with either IgG (5 mg/kg) or T2.5 (5 mg/kg) weekly for 4 weeks. a Representative images from immunohistochemical staining of NeuN in the
neocortex and hippocampus of mice. The numbers of NeuN positive cells were counted in the neocortex and hippocampus of mice (n = 6 per
group). b Representative images from immunohistochemical staining of Thyroxine hydroxylase (TH) in the antibody-administrated mice. The level of
TH was analyzed by optical density quantification and the numbers of TH positive cell were counted in the striatum and substantia nigra of mice,
respectively (n = 6 per group). c Immunoblotting analysis of whole-brain lysates. The lysates were probed for active form of casepase-3 and β-actin.
The level of active caspase 3 was determined by densitometric quantification (n = 3 per group). d–f Behavioral analysis of the mice. The total activity
(d), latency (e), and thigmotaxis (f) were analyzed by open field test (n = 6 per group). Data are mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001;
one way ANOVA. Scale bar, 25 μm
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Fig. 6 (See legend on next page.)
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with pam3CSK4 significantly increased both the fluor-
escence levels and the diameter of fluorescent puncta
in recipient neuronal cells (Fig. 6b). TLR2 activation
also increased the activity of caspase-3 in recipient cells
(Fig. 6b). Similarly, overexpression of TLR2 with lenti-
viral vectors significantly increased the fluorescence levels,
the diameter of fluorescent puncta, and caspase-3 activity
in recipient cells (Fig. 6c). In contrast, these increases were
reversed by lentivirus-mediated TLR2 gene knockdown
(Fig. 6d) and anti-TLR2 treatment (Fig. 6e). Since we dem-
onstrated TLR2 mediated neuron-to-neuron α-synuclein
transmission, we next examined the role of TLR2 in
α-synuclein internalization process by recipient neurons
(Fig. 6f). Differentiated SH-SY5Y neuronal cells (dSY5Y)
were exposed to α-synuclein conditioned medium (αSCM)
[7] which contains neuron-released α-synuclein for 8 and
24 h α-synuclein (Fig. 6f). In neuronal recipient cells, ex-
posure of αSCM led to internalization of α-synuclein in a
time-dependent manner (Fig. 6f). At 8 h, internalized
α-synuclein formed small intracellular puncta, but formed
large inclusion body-like aggregates at 24 h (Fig. 6f). How-
ever, it was significantly decreased when dSY5Y cells were
exposed to αSCM in the presence of T2.5 (Fig. 6f). Simi-
larly, treatment with the αSCM resulted in increased in-
ternalization of α-synuclein and activation of caspase-3 in
primary neurons, while treatment with the ant-TLR2 anti-
body significantly blocked internalization of α-synuclein
and activation of caspase-3 (Fig. 6g). Human α-synuclein
was not detected and caspase-3 activity was not affected
in mouse primary neurons treated with LZCM (control
conditioned medium, obtained from β-galactosidase
overexpressing neuronal cells) (Fig. 6g). Collectively,
these results support that TLR2 modulates neurotoxic
α-synuclein accumulation through mediation of neuron-
to-neuron α-synuclein transmission and that treatment
with the neutralizing TLR2 antibody reduces α-synuclein
accumulation and neurotoxicity.
Antagonizing TLR2 decreases astroglial α-synuclein
accumulation and inflammatory responses
Since the astrocytes in the α-Syn-tg mice do not express
human-α-synuclein and TLR2 expression is increased in
glial cells in these mice (Fig. 1e and f), our findings
indicate that the neuro-inflammation and increased ac-
cumulation of α-synuclein in glial cells in the α-Syn-tg
(Fig. 4), might be the result of neuron to astrocyte trans-
mission. Moreover, since T2.5 ameliorated these effects
(Fig. 4) we propose that TLR2 might be a mediator of
the accumulation of α-synuclein in glial cells. To better
understand the mechanisms of action of the antibody,
we utilized a modified in vitro α-synuclein transmission
live cell (neuron-to-astrocyte) monitoring system
(Fig. 7a). We co-cultured donor neurons with recipient
human primary astrocytes (Fig. 7a). Donor neuronal cells
(V1S), expressing the amino-terminal venus-α-synuclein
fusion protein, were incubated in trans-well inserts and
recipient astrocytes were placed in lower compartments
(Fig. 7a). After 3 days of co-culture, the recipient astro-
cytes were immune-labelled with anti-venus antibody to
verify the transferred N-term venus-tagged α-synuclein
from neuronal V1S cells (Fig. 7a). Immunolabeling
analysis revealed the transmission of venus-tagged
α-synuclein from neuronal cells to astrocytes after a 3-day
co-culture (Fig. 7b). In addition, overexpression of
TLR2 significantly increased the immune-reactivity against
venus protein in astrocytes, while it was decreased by
lentiviral vector-mediated TLR2 gene knockdown and
anti-TLR2 administration (Fig. 7b and c). Co-culture of as-
trocytes with α-synuclein-expressing neuronal cells also in-
duced expression of IL-6, a pro-inflammatory cytokine gene,
in astrocytes (Fig. 7b and c). Although TLR2 overexpression
did not induce further increase of IL-6 expression in
co-cultured astrocyte, IL-6 levels were significantly reduced
by lentiviral vector-mediated TLR2 gene knockdown or by
treatment with the anti-TLR2 antibody (Fig. 7b and c).
(See figure on previous page.)
Fig. 6 TLR2 mediates neurotoxic neuron-to-neuron α-synuclein transmission. a Overview diagram. Donor neuronal cells (V1S), expressing α-
synuclein-conjugated with N-terminus of venus were plated in trans-well insert and the recipient neuronal cells (SV2), expressing α-synuclein
conjugated with C-terminus of venus were seeded onto cover slips in the bottom well. Only SV2 cells were treated with pam3CSK4 (10 μg/ml),
lentiviral vectors, or antibodies. Images were taken from SV2 cells after a 3-days co-culture. b–e Representative confocal images for BiFC fluorescence
and caspase-3 activity in SV2 cells. Middle panels are enlargements of cropped regions outlined with dashed lines from upper panels. Lower panels are
double-immunolabeling assay with active casepase-3. The average numbers of venus fluorescence intensity in each cell, the average size of
the venus punctum diameters, and caspase-3 fluorescence intensity were analyzed. b V1S and SV2 cells were co-cultured in the presence or
absence of pam3CSK4 (10 μg/ml) (n = 3). c V1S and SV2 cells were co-cultured with either LV-control or LV-TLR2 (n = 3). d V1S and SV2 cells
were co-cultured with either LV-sh.control or LV-shTLR2 (n = 3). e V1S and SV2 cells were co-cultured with either IgG (5 μg/ml) or T2.5 (5 μg/ml)
(n = 3). f The kinetics of α-synuclein internalization in the presence of antibodies. dSY5Y cells were incubated with αSCM for indicated hours in the
presence of either IgG (5 μg/ml) or T2.5 (5 μg/ml). The kinetics was analyzed by immunolabeling assay (n = 3). g Neuronal internalization of
α-synuclein in the presence of antibodies. Mouse primary cortical neurons were incubated with αSCM or LZCM for indicated hours in the
presence of either IgG (5 μg/ml) or T2.5 (5 μg/ml). Neurons were double immunolabelled with human α-synuclein (Middle panels) and
active form of caspase-3 (low panels) (n = 3). Data are mean ± SEM (n = 3 per group). *p < 0.05, **p < 0.01, and ***p < 0.001; unpaired t test
for all analysis except (g) (one way ANOVA). Scale bar, 20 μm
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Next, we examined the role of TLR2 in α-synuclein in-
ternalization in recipient astrocytes and if treatment of
anti-TLR2 blocks this process (Fig. 7d). Primary human
astrocytes were exposed to αSCM for 8 and 24 h in the
presence of either control IgG or anti-TLR2 (Fig. 7d). In
recipient astrocytes, internalization of α-synuclein was
increased in both IgG and anti-TLR2 treated cells at the
early time point (8 h) (Fig. 7d). However, it was signifi-
cantly reduced by TLR2 inhibition at the late time point
(24 h) (Fig. 7d). This is consistent with the in vivo stud-
ies showing increased accumulation of α-synuclein in
astrocytes in the IgG treated α-Syn-tg and that anti-
TLR2 treatment reduced the astroglial accumulation of
α-synuclein (Fig. 4c). Moreover, exposure to extracellular
α-synuclein induced astroglial expressions of the pro-
inflammatory cytokines and chemoattractant chemokines,
such as IL-1β, IL-6, CCL5, and CX3CL1, while those ele-
vations were completely inhibited by anti-TLR2 treatment
(Fig. 7e-h). Immunoblotting analysis also revealed that
exposure to α-synuclein induced activation of NFκB
and p38 MAPK in astrocytes (Fig. 7i). Collectively, these
results suggest that TLR2 modulates astroglial α-synuclein
Fig. 7 Astrocyte responses by TLR2 mediated neuron-to-astrocyte α-synuclein transmission. a Overview diagram. Donor neuronal cells (V1S),
expressing α-synuclein-conjugated with N-terminus of venus were plated in trans-well insert and the recipient human primary astrocytes were
plated onto the cover slips in the bottom well. Only astrocytes were treated with either lentiviral vectors or antibodies. Images were taken from
astrocytes after a 3-days co-culture. b, c Representative confocal images for N-terminus of venus (Upper panel) and IL-6 (Lower panel) in recipient
astrocytes. The fluorescence intensity of N-term venus and IL-6 were analyzed in randomly chosen area. b V1S and astrocytes were co-cultured in
the presence of either LV-control/sh.control, LV-TLR2, or LV-sh.TLR2 (n = 3). c V1S and astrocytes were co-cultured in the presence of either IgG
(5 μg/ml) or T2.5 (5 μg/ml) (n = 3). d The kinetics of astroglial α-synuclein internalization in the presence of antibodies. Human primary astrocytes
were incubated with αSCM for indicated hours in the presence of either IgG (5 μg/ml) or T2.5 (5 μg/ml). The kinetics was analyzed by immunolabeling
assay (n = 3). e–h Quantitative analysis of the cytokine/chemokine gene expressions in astrocytes. The cells were incubated with either LZCN or αSCM
for 24 h in the presence of indicated antibodies. The expressions of IL-1β (e), IL-6 (f), CCL5 (g), and CX3CL1 (h) were normalized to the levels of β-actin
(n = 4). Data are mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001; one way ANOVA for all analysis except (d) (unpaired t test). Scale bar, 20 μm
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accumulation through neuron-to-astrocyte α-synuclein
transmission, thereby regulates astroglial responses, and
the blocking of this effect might underlie the neuroprotec-
tive and immunomodulatory effects of the anti-TLR2
treatment.
Discussion
The present study showed that administration of anti-
TLR2 alleviated α-synuclein accumulation in neuronal
and astroglial cells, neuroinflammation, neurodegener-
ation, and functional deficits in the mouse model of
PD/DLB. Moreover, in vitro studies with neuronal and
astroglial cells showed that the anti-TLR2 blocks NFκB
dependent pro-inflammatory responses by blocking the
neuron-to-neuron and neuron-to-astrocyte α-synuclein
transmission. While for this study we focused on the
effects of blocking TLR2 on glial and NFκB dependent
neuro-inflammatory responses, in previous studies we
investigated the pathological roles of TLR2 in neurons
in in vitro and in vivo models of synucleinopathy [8].
In neurons, extracellular α-synuclein inhibited autophagy
in a TLR2 dependent manner via mTOR and AKT signal-
ing cascades [8]. Thus, activation and gene overexpression
of TLR2 induced abnormal accumulation of α-synuclein
aggregates in neuron followed by accumulation autophagy
markers, such as p62SQS/TM1 [8]. We have also shown
the pathogenic interaction of TLR2 and α-synuclein in
microglia [7]. The oligomeric forms of extracellular
α-synuclein interacts with TLR2 on the surface of microglia,
thereby induced neurotoxic microglia activation through
NFκB and p38 MAPK signaling cascades [7]. Once acti-
vated, microglia produced neurotoxic by-products, such as
inflammatory cytokines, reactive oxygen species, and nitric
oxides [7].
Another new finding of this study, is that in addition of
the microglia, extracellular α-synuclein induced astroglial
responses which are neurotoxic. Once exposed to α-
synuclein, astrocytes expressed pro-inflammatory cytokine
expressions through NFκB and p38 MAPK signaling cas-
cades (Fig. 8). Therefore, we targeted TLR2 in in vivo and
in in vitro models of synucleinopathy using a functional
inhibitory antibody (T2.5). Remarkably, the administra-
tion of TLR2 functional blocking antibody significantly
reduced α-synuclein depositions in neurons and astro-
glial cells as well ameliorating neurodegeneration, neuro-
inflammation, and NFκB activation. The in vivo results
Fig. 8 Model for TLR2 immunotherapy ameliorates neurodegeneration in synucleinopathy. In disease condition, TLR2 mediates neurotoxicity. In
neuron, i) TLR2 induces pathological internalization of extracellular α-synuclein into neuron and ii) extracellular α-synuclein activates neuronal
TLR2 which results in mTOR-mediated autophagy inhibition. Thus, neuronal TLR2 induces neurotoxic α-synuclein accumulation. In astrocyte, iii)
TLR2 increased abnormal α-synuclein accumulation which leads astroglial activation and iv) extracellular α-synuclein activates astroglial TLR2
signaling cascade through NFκB/p38 MAPK which results in neurotoxic astroglial responses such as pro-inflammatory cytokine expression and
induction of reactive microglia recruiting chemokines. Therefore, TLR2 immunotherapy ameliorates α-synuclein-mediated neurotoxicity via
inhibition of 1) TLR2-mediated neuronal α-synuclein internalization, 2) activation of neuronal autophagy via TLR2-mTOR signaling cascade, 3)
inhibition of TLR2-mediated astroglial responses, and 4) reduction of astroglial α-synuclein accumulation. Thereby, TLR2 immunotherapy might be
a novel therapeutic strategy for synucleinopathy
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were confirmed in vitro where treatment with the
anti-TLR2 decreased internalization of α-synuclein into
neuron and astrocytes and this was accompanied by de-
creased expression of pro-inflammatory cytokines and
signaling via the p38/MAPK and NFκB pathway. There-
fore, these results support that TLR2 plays key roles in
the pathogenesis of synucleinopathy and functional inhib-
ition of TLR2 ameliorates neuropathology in synucleino-
pathy through inhibition of pathogenic neuron-to-neuron
and neuron-to-astrocyte α-synuclein transmission, clear-
ance of accumulated neurotoxic α-synuclein via autoph-
agy, and inhibition of astroglial inflammatory responses
(Fig. 8).
The steady state levels of α-synuclein could be affected
by various different factors including gene expression
and proteostasis. In particular, it has been suggested that
the clearance of α-synuclein could be determined by as-
sembly state of the protein [4, 40]. Autophagy/lysosomal
pathway is involved in the clearance of oligomeric and
fibrilar species of α-synuclein [41–43], while monomeric
and dimeric α-synuclein species are degraded by ubiquitin-
proteasome system and chaperone-mediated autophagy
[44, 45]. We previously have shown that functional in-
hibition of TLR2 activated autophagy process in neuron
[8]. Consistent with these findings, in current study, we
observed a significant reduction of triton-insoluble
α-synuclein oligomers in T2.5 administrated α-Syn-tg
while the level of α-synuclein monomer was not af-
fected by antibody administrations (Fig. 3d). Together,
these results suggest that administration of TLR2 func-
tional inhibitory antibody reduced accumulation of neuro-
toxic α-synuclein oligomers through autophagy-mediated
clearance in an animal model of PD.
There is growing evidence that receptor-mediated trans-
mission of α-synuclein is responsible for the spreading of
synucleinopathy lesions in PD/DLB. Recent studies have
suggested LAG3 that might be such a receptor that oper-
ates by mediating seeding and transmission of α-synuclein
fibrils [9], but the details are still largely unknown. Our
study is different in that we focused on the effects of block-
ing TLR2 which is a mediator of the neurotoxic and
pro-inflammatory of extracellular α-synuclein oligomers.
We have previously shown that TLR2 is not activated by
recombinant fibrils as is the case for LAG3 but rather by
neuron-released extracellular α-synuclein oligomers [7].
Using α-synuclein conformation specific antibodies, we
also demonstrated that α-synuclein oligomers mainly con-
tributed to neuron-to-neuron α-synuclein transmission/
propagation instead of fibril forms in a recent study [46].
Neuron-to-neuron α-synuclein transmission was signifi-
cantly decreased in the presence of oligomer conformation
specific antibodies in this BiFC α-synuclein monitoring sys-
tem, while it was not affected by fibril specific antibodies
[46]. In addition, the caspase-3 activities were increased in
proportion to the levels of small size of venus puncta in re-
cipient neuronal cells. Together, these results support that
oligomer is a main contributor of pathogenic cell-to-cell
α-synuclein transmission.
Although most studies have focused at investigating
the accumulation of α-synuclein in neurons, there is grow-
ing evidence that α-synuclein accumulates in astrocytes in
the brains of patients with PD/DLB [47–51]. Consistent
with these observations, in the present study we show that
α-synuclein accumulates in astrocytes of the α-Syn-tg mice
and that is associated with increased TLR2 expression,
pro-inflammatory cytokines, and NFκB activation.
Treatment with anti-TLR2 blocked these effects in in
vivo. We have previously shown that neuron-to-astrocyte
α-synuclein transmission might be an undelaying pathway
for α-synuclein accumulation in astrocytes [33]. In
addition, in the current study, we verified the central role
of TLR2 in astroglial α-synuclein accumulation. Overex-
pression of astroglial TLR2 significantly increased astro-
glial α-synuclein internalization as well as neuron-
to-astrocyte α-synuclein transmission in in vitro synuclei-
nopathy model system, while those were inhibited by
anti-TLR2 treatment and TLR2 gene knockdown. Interest-
ingly, the internalization of α-synuclein was not affected
by TLR2 functional inhibition at the early time point in
α-synuclein-exposed astrocyte. This result suggests
the existence of TLR2-independent astrocyte-specific
α-synuclein internalization mechanisms. However, the
level of internalized α-synuclein was significantly re-
duced by TLR2 functional inhibition at the late time
point exposure. This also suggests that TLR2 activity
might be associated with a clearance mechanism of ac-
cumulated α-synuclein in the astrocyte. In addition,
TLR2-dependent astroglial α-synuclein accumulation
triggered neurotoxic astroglial pro-inflammatory responses
through NFκB and p38 MAPK signaling cascades (Fig. 8).
Interestingly, α-synuclein-exposed astrocytes also induced
chemoattractant chemokine expressions, such as CCL5
and CXCL1 which are recruiting neurotoxic reactive
microglial cells into affected brain regions [52]. Thereby,
these findings suggest that TLR2 mediates astroglial
α-synuclein accumulation through neuron-to-astroglial
α-synuclein transmission and may contribute to local
immune response in patients with DLB/PD, and that treat-
ment with anti-TLR2 antibody might block the neuropath-
ology by blocking NFκB and p38 MAPK signaling in
astrocytes.
While the numbers of TLR2 positive microglia cells
were increased in the brains of PD/DLB patients and
mouse models [7, 34, 53], we were not able to observed
extensive microglial α-synuclein deposition in our current
in vivo study. In addition, we failed to demonstrate the
neuron-to-microglial α-synuclein transmission using the
in vitro transmission assay. Instead, we found that once
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internalized, α-synuclein was rapidly cleared from
microglia regardless of TLR2 activity (data not shown).
Together with our previous findings [54], these results
suggest that microglia are the most efficient cells for
removal of extracellular α-synuclein in the brain and
may have a distinct specific mechanism for degradation
and clearance of internalized α-synuclein aggregates. There-
fore, microglia might be a candidate for cell-based thera-
peutics against synucleinopathies to remove pathogenic
forms of extracellular α-synuclein.
For over two decades, immunotherapy has been pro-
posed as a potential treatment approach for neurodegen-
erative disorders of the aging population such as AD and
PD/DLB. In the field of synucleinopathies, considerable
progress has been made by developing active [22, 55], pas-
sive [32, 46, 56–60], and cellular [19, 61, 62] immunother-
apeutic approaches of which a few of them have moved to
clinical trials [63]. Since α-synuclein is a key pathological
mediator in the disorders with parkinsonism and demen-
tia, most of studies have targeted monomeric, oligomeric,
and fibrilar α-synuclein [64]. However, the characteristics
of the physiological vs pathogenic forms of α-synuclein
is still enigmatic [65]. Thus, in addition of targeting
α-synuclein it might necessary to develop therapeutics
for alternative pathways such as neuro-inflammation, au-
tophagy, transcriptional regulation, and mitochondrial
energetic and biogenesis [4, 65].
Conclusions
In this context we propose immunotherapy targeting
TLR2, given its role as a mediator of the neurotoxic and
pro-inflammatory effects of extracellular α-synuclein olig-
omers. Such therapy might be suitable for combinatorial
approaches with molecules interfering with α-synuclein or
pathways relevant to neuro-inflammation, autophagy and
mitochondrial energetic and biogenesis [27]. In summary,
we propose that TLR2 is a novel target for immunother-
apy and a potentially viable therapeutic strategy for synu-
cleinopathies of the aging population.
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